Daniel Ferreira

Daniel Ferreira has extensive experience in regulatory chemistry, manufacturing, and controls (CMC), with a focus on oligonucleotide programs and small molecule analytical development. At Stoke Therapeutics, Daniel served as Senior Director and Director, overseeing the preparation, review, and quality oversight of CMC submission documents, including INDs, IMPDs, and NDAs. Prior experience at Sarepta Therapeutics included roles as Senior Director and Director of Regulatory CMC, as well as Associate Director, contributing to various CMC submissions. Daniel’s background also includes positions at AVEO Oncology, Biogen Idec, and GlaxoSmithKline, contributing to analytical method development and quality assurance. Daniel earned a Ph.D. in Analytical Chemistry from the University of Massachusetts Amherst and a B.S. in Chemistry from the University of Massachusetts Lowell.